| 3G1L | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM14744 |
| 3G1M | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM31381 |
| 3G1O | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM14500 |
| 3O8G | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM14801 |
| 3O8H | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM14950 |
| 3Q0U | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM31379 |
| 3Q0V | A:22-92; B:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM31369 |
| 3Q0W | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM33066 |
| 3Q3S | A:22-94 | ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH COMPOUND BDM5683 |
| 3SDG | A:26-92 | ETHIONAMIDE BOOSTERS PART 2: COMBINING BIOISOSTERIC REPLACEMENT AND STRUCTURE-BASED DRUG DESIGN TO SOLVE PHARMACOKINETIC ISSUES IN A SERIES OF POTENT 1,2,4-OXADIAZOLE ETHR INHIBITORS. |
| 3SFI | A:22-94 | ETHIONAMIDE BOOSTERS PART 2: COMBINING BIOISOSTERIC REPLACEMENT AND STRUCTURE-BASED DRUG DESIGN TO SOLVE PHARMACOKINETIC ISSUES IN A SERIES OF POTENT 1,2,4-OXADIAZOLE ETHR INHIBITORS. |
| 4DW6 | A:24-93 | NOVEL N-PHENYL-PHENOXYACETAMIDE DERIVATIVES AS POTENTIAL ETHR INHIBITORS AND ETHIONAMIDE BOOSTERS. DISCOVERY AND OPTIMIZATION USING HIGH-THROUGHPUT SYNTHESIS. |
)
)